3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
2
Status
Recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Sarcoma
1
Lymphoid
1
Gastrointestinal
1
CNS
1
Conditions
Neoplasms
4
Lung Neoplasms
3
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Hematologic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Stomach Neoplasms
1
Sarcoma
1
Neuroblastoma
1
Lymphoproliferative Disorders
1
Glioma
1
Adenocarcinoma of Lung
1
Interventions
Cyclophosphamide
22
fludarabine
20
venetoclax
8
Whole-Body Irradiation
8
Mycophenolic Acid
8
Standard of Care
6
Mesna
6
Melphalan
6
Azacitidine
6
fludarabine phosphate
5
Sirolimus
5
thymoglobulin
4
Thiotepa
4
Tacrolimus
4
Surveys and Questionnaires
4
Specimen Handling
4
Filgrastim
4
Cytarabine
4
entrectinib
3
daratumumab
3
cobimetinib
3
alectinib
3
Vemurafenib
3
Rituximab
3
Practice Guidelines as Topic
3
Palliative Care
3
Granulocyte Colony-Stimulating Factor
3
Busulfan
3
Bortezomib
3
Blood Specimen Collection
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Hematologic Neoplasms
×
capmatinib
×
Clear all
NCT05722886
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
825 enrolled
NCT06988475
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled